JP2022523201A5 - - Google Patents
Info
- Publication number
- JP2022523201A5 JP2022523201A5 JP2021549575A JP2021549575A JP2022523201A5 JP 2022523201 A5 JP2022523201 A5 JP 2022523201A5 JP 2021549575 A JP2021549575 A JP 2021549575A JP 2021549575 A JP2021549575 A JP 2021549575A JP 2022523201 A5 JP2022523201 A5 JP 2022523201A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- hydrogen
- compound
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19159299.7 | 2019-02-26 | ||
| EP19159299 | 2019-02-26 | ||
| PCT/EP2020/054897 WO2020173935A1 (en) | 2019-02-26 | 2020-02-25 | New isoindolinone substituted indoles and derivatives as ras inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523201A JP2022523201A (ja) | 2022-04-21 |
| JP2022523201A5 true JP2022523201A5 (enExample) | 2023-03-03 |
| JP7426398B2 JP7426398B2 (ja) | 2024-02-01 |
Family
ID=65598476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549575A Active JP7426398B2 (ja) | 2019-02-26 | 2020-02-25 | Ｒａｓ阻害剤としての新規イソインドリノン置換インドールおよび誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12281099B2 (enExample) |
| EP (1) | EP3931188B1 (enExample) |
| JP (1) | JP7426398B2 (enExample) |
| CN (1) | CN113474340B (enExample) |
| WO (1) | WO2020173935A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| AU2021263914B2 (en) | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| EP4313151A1 (en) | 2021-03-31 | 2024-02-07 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
| GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
| CN115232108B (zh) | 2021-04-23 | 2025-04-18 | 领泰生物医药(绍兴)有限公司 | Sos1降解剂及其制备方法和应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023060362A1 (en) * | 2021-10-15 | 2023-04-20 | Genetolead Inc. | Ras inhibitors, compositions and methods of use thereof |
| TW202334136A (zh) * | 2021-11-03 | 2023-09-01 | 美商傳達治療有限公司 | PI3Kα抑制劑及其製造與使用方法 |
| WO2023114973A1 (en) | 2021-12-17 | 2023-06-22 | Shure Acquisition Holdings, Inc. | Adaptive acoustic echo cancellation for a stereo audio signal |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CA3244999A1 (en) | 2022-03-31 | 2025-06-13 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4598538A1 (en) | 2022-10-05 | 2025-08-13 | Sevenless Therapeutics Limited | New treatments for pain |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| KR20250166103A (ko) | 2023-04-06 | 2025-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료용 약제학적 조성물 |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0810082A2 (pt) * | 2007-03-29 | 2014-10-21 | Novartis Ag | 3-imidazolil-indóis para o tratamento de doenças proliferativas |
| TW201524952A (zh) | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Ｋｒａｓ ｇ１２ｃ之共價抑制劑 |
| MX380928B (es) | 2013-10-10 | 2025-03-12 | Araxes Pharma Llc | Inhibidores de kras g12c. |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| JP6869947B2 (ja) | 2015-07-22 | 2021-05-12 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用 |
| WO2017068412A1 (en) * | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| US10377743B2 (en) * | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| EP3573971A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2021148581A1 (en) * | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
-
2020
- 2020-02-25 EP EP20707599.5A patent/EP3931188B1/en active Active
- 2020-02-25 CN CN202080016480.4A patent/CN113474340B/zh active Active
- 2020-02-25 WO PCT/EP2020/054897 patent/WO2020173935A1/en not_active Ceased
- 2020-02-25 JP JP2021549575A patent/JP7426398B2/ja active Active
- 2020-02-25 US US17/430,011 patent/US12281099B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10844080B2 (en) | Compositions and methods for inhibiting arginase activity | |
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| US9221801B2 (en) | Inhibitors of histone demethylases | |
| JP2021532162A5 (enExample) | ||
| JP2006503082A5 (enExample) | ||
| JP2009509961A5 (enExample) | ||
| RU2004111979A (ru) | Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью | |
| JP2022549222A5 (enExample) | ||
| JP2004511466A5 (enExample) | ||
| JP2010500415A5 (enExample) | ||
| JP2014527082A5 (enExample) | ||
| JP2015510886A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2017506250A5 (enExample) | ||
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| RU2014145856A (ru) | Азотсодержащее гетероциклическое соединение или его соль | |
| JP2007511504A5 (enExample) | ||
| RU2013151174A (ru) | Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы | |
| JP2014516360A5 (enExample) | ||
| RU2008119842A (ru) | Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1 | |
| JP2016510000A5 (ja) | 治療用化合物 | |
| JP2014520108A5 (enExample) | ||
| JP2013532668A5 (enExample) | ||
| JP2007505044A5 (enExample) | ||
| JP2023532128A5 (enExample) |